The rationale for combination therapy

American Journal of Cardiology

Volumn 90, Issue 10 SUPPL. 2, 2002, Pages 2-7

  Rosenson, Robert S ^a  

^a NORTHWESTERN UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ATORVASTATIN; BILE ACID; C REACTIVE PROTEIN; FIBRIC ACID DERIVATIVE; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; LOW DENSITY LIPOPROTEIN CHOLESTEROL; MEVINOLIN; NICOTINIC ACID; PRAVASTATIN; SIMVASTATIN; TRIACYLGLYCEROL;

ANGIOCARDIOGRAPHY; ARTICLE; CARDIOVASCULAR RISK; CHOLESTEROL TRANSPORT; CORONARY ARTERY OBSTRUCTION; DISEASE COURSE; DRUG EFFECT; DRUG EFFICACY; DYSLIPIDEMIA; HUMAN; ISCHEMIC HEART DISEASE; MORBIDITY; MORTALITY; PRACTICE GUIDELINE; PREDICTION; PRIORITY JOURNAL;

EID: 0037146282     PISSN: 00029149     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0002-9149(02)02966-1     Document Type: Article

References (28)

1. Brown A.S., Bakker-Arkema R.G., Yellen L., Helney R.W., Guthrie R., Campbell C.F., Koren M., Woo W., McLain R., Black D.M. Treating patients with documented atherosclerosis to National Cholesterol Education Program-recommended low-density-lipoprotein cholesterol goals with atorvastatin, fluvastatin, lovastatin and simvastatin. J Am Coll Cardiol. 32:1998;665-672.
2. MRC/BHF Heart Protection Study of cholesterol-lowering therapy and of antioxidant vitamin supplementation in a wide range of patients at increased risk of coronary heart disease death early safety and efficacy experience . Eur Heart J. 20:1999;725-741.
3. Prevention of cardiovascular events and death with pravastatin in patients with coronary heart disease and a broad range of initial cholesterol levels. N Engl J Med. 339:1998;1349-1357.
4. Randomized trial of cholesterol lowering in 4444 patients with coronary heart disease the Scandinavian Simvastatin Survival Study (4S) . Lancet. 344:1994;1383-1389.
5. Sacks F.M., Pfeffer M.A., Moye L.A., Rouleau J.L., Rutherford J.D., Cole T.G., Brown L., Warnica J.W., Arnold J.M., Wun C.C., Davis B.R., Braunwald E. The effect of pravastatin on coronary events after myocardial infarction in patients with average cholesterol levels. Cholesterol and Recurrent Events Trial investigators. N Engl J Med. 335:1996;1001-1009.
6. Simes J., Furberg C.D., Braunwald E., Davis B.R., Ford I., Tonkin A., Shepherd J. Effects of pravastatin on mortality in patients with and without coronary heart disease across a broad range of cholesterol levels. The Prospective Pravastatin Pooling project. Eur Heart J. 23:2002;207-215.
7. Shepherd J., Cobbe S.M., Ford I., Isles C.G., Lorimer A.R., MacFarlane P.W., McKillop J.H., Packard C.J. Prevention of coronary heart disease with pravastatin in men with hypercholesterolemia. West of Scotland Coronary Prevention Study Group. N Engl J Med. 333:1995;1301-1307.
8. Downs J.R., Clearfield M., Weis S., Whitney E., Shapiro D.R., Beere P.A., Langendorfer A., Stein E.A., Kruyer W., Gotto A.M. Jr. Primary prevention of acute coronary events with lovastatin in men and women with average cholesterol levels results of AFCAPS/TexCAPS. Air Force/Texas Coronary Atherosclerosis Prevention Study . JAMA. 279:1998;1615-1622.
9. Rosenson R.S. Beyond low-density lipoprotein cholesterol. A perspective on low high-density lipoprotein disorders and Lp(a) lipoprotein excess. Arch Intern Med. 156:1996;1278-1284.
10. Ridker P.M., Shih J., Cook T.J., Clearfield M., Downs J.R., Pradhan A.D., Weis S.E., Gotto A.M. Jr. Plasma homocysteine concentration, statin therapy, and the risk of first acute coronary events. Circulation. 105:2002;1776-1779.
11. Rosenson R.S., Koenig W. High-sensitivity C-reactive protein and cardiovascular risk in patients with coronary heart disease. Curr Opin Cardiol. 17:2002;325-331.
12. Koenig W., Rosenson R.S. Emerging risk factors acute-phase reactants. Supplement on risk factors for coronary heart disease . Seminars in Vascular Medicine. 2002.
13. Sacks F.M., Tonkin A.M., Shepherd J., Braunwald E., Cobbe S., Hawkins C.M., Keech A., Packard C., Simes J., Byington R., Furberg C.D. Effect of pravastatin on coronary disease events in subgroups defined by coronary risk factors the Prospective Pravastatin Pooling Project . Circulation. 102:2000;1893-1900.
14. Gotto A.M. Jr, Whitney E., Stein E.A., Shapiro D.R., Clearfield M., Weis S., Jou J.Y., Langendorfer A., Beere P.A., Watson D.J., Downs J.R., de Cani J.S. Relation between baseline and on-treatment lipid parameters and first acute major coronary events in the Air Force/Texas Coronary Atherosclerosis Prevention Study (AFCAPS/TexCAPS). Circulation. 101:2000;477-484.
15. Pekkanen J., Linn S., Heiss G., Suchindran C.M., Leon A., Rifkind B.M., Tyroler H.A. Ten-year mortality from cardiovascular disease in relation to cholesterol level among men with and without preexisting cardiovascular disease. N Engl J Med. 322:1990;1700-1707.
16. Brown B.G., Zhao X.Q., Chait A., Fisher L.D., Cheung M.C., Morse J.S., Dowdy A.A., Marino E.K., Bolson E.L., Alaupovic P., Frohlich J., Albers J.J. Simvastatin and niacin, antioxidant vitamins, or the combination for the prevention of coronary disease. N Engl J Med. 345:2001;1583-1592.
17. Haskell W.L., Alderman E.L., Fair J.M., Maron D.J., Mackey S.F., Superko H.R., Williams P.T., Johnstone I.M., Champagne M.A., Krauss R.M. Effects of intensive multiple risk factor reduction on coronary atherosclerosis and clinical cardiac events in men and women with coronary artery disease. The Stanford Coronary Risk Intervention Project (SCRIP). Circulation. 89:1994;975-990.
18. Mack W.J., Krauss R.M., Hodis H.N. Lipoprotein subclasses in the Monitored Atherosclerosis Regression Study (MARS). Treatment effects and relation to coronary angiographic progression. Arterioscler Thromb Vasc Biol. 16:1996;697-704.
19. Watts G.F., Mandalia S., Brunt J.N., Slavin B.M., Coltart D.J., Lewis B. Independent associations between plasma lipoprotein subfraction levels and the course of coronary artery disease in the St. Thomas' Atherosclerosis Regression Study (STARS). Metabolism. 42:1993;1461-1467.
20. Zambon A., Hokanson J.E., Brown B.G., Brunzell J.D. Evidence for a new pathophysiological mechanism for coronary artery disease regression hepatic lipase-mediated changes in LDL density . Circulation. 99:1999;1959-1964.
21. Rosenson R.S., Otvos J.D., Freedman D.S. Relations of lipoprotein subclass levels and low-density lipoprotein size to progression of coronary artery disease in the pravastatin limitation of atherosclerosis in the coronary arteries (PLAC-I) trial. Am J Cardiol. 90:2002;89-94.
22. Campos H., Moye L.A., Glasser S.P., Stampfer M.J., Sacks F.M. Low-density lipoprotein size, pravastatin treatment, and coronary events. JAMA. 286:2001;1468-1474.
23. Otvos J.D., Shalaurova I., Freedman D.S., Rosenson R.S. Effects of pravastatin treatment on lipoprotein subclass profiles and particle size in the PLAC-I trial. Atherosclerosis. 160:2002;41-48.
24. McKenney J.M., McCormick L.S., Schaefer E.J., Black D.M., Watkins M.L. Effect of niacin and atorvastatin on lipoprotein subclasses in patients with atherogenic dyslipidemia. Am J Cardiol. 88:2001;270-274.
25. Ballantyne C.M., Olsson A.G., Cook T.J., Mercuri M.F., Pedersen T.R., Kjekshus J. Influence of low high-density lipoprotein cholesterol and elevated triglyceride on coronary heart disease events and response to simvastatin therapy in 4S. Circulation. 104:2001;3046-3051.
26. Executive Summary of the Third Report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III). JAMA. 285:2001;2486-2497.
27. Caslake M.J., Packard C.J., Gaw A., Murray E., Griffin B.A., Vallance B.D., Shepherd J. Fenofibrate and LDL metabolic heterogeneity in hypercholesterolemia. Arterioscler Thromb. 13:1993;702-711.
28. Davidson M. Strategies to improve Adult Treatment Panel III guideline adherence and patient compliance. Am J Cardiol. 89:2002;8C-22C.